Answers are grounded in this paper and cite their sources.
HER2-low breast cancer has emerged as a distinct subtype with unique biological characteristics. Habitat imaging can characterize intratumoral heterogeneity by partitioning tumors into subregions with distinct imaging phenotypes. However, the comparative prognostic value of habitats derived from diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) remains unexplored. This study aimed to develop and compare DWI and DCE habitat radiomics models for predicting disease-free survival (DFS) in HER2-low breast cancer. A total of 401 patients from four centers were retrospectively included. DWI and DCE images were independently clustered into three habitats using K-means, relabeled by signal intensity as low (L), medium (M), and high (H). From each habitat, 107 three-dimensional radiomics features were extracted. LASSO-Cox regression with 5-fold cross-validation was used for model construction. Model performance was assessed by C-index, time-dependent AUC, Brier score, and log-rank test. Among pure imaging models, the DCE high-signal habitat (DCE_H) demonstrated the best performance (C-index = 0.642, P = 0.033). When combined with clinical variables, the DCE_H model achieved modestly higher time-dependent AUC on nested cross-validation (3-year AUC 0.699→0.720; 5-year AUC 0.728→0.754), although this incremental difference did not reach statistical significance in paired comparison ( P = 0.056 and 0.080, respectively). Standard multivariable Cox regression suggested that DCE_H Sphericity was associated with DFS (hazard ratio [HR] = 0.067, 95% confidence interval [CI]: 0.010–0.520, P = 0.0096). In contrast, DWI habitat features were not selected by LASSO when clinical variables were present. DCE high-signal habitat radiomics—particularly Sphericity—was associated with DFS in HER2-low breast cancer, although its incremental value over clinical variables was modest and not statistically significant. DWI features added little. External validation is required. The study was retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR2400085188, registered June 03, 2024, http//www.chictr.org.cn/).
No takes yet. Share an insight, caveat, or question.
Meng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: